J B Chemicals & Pharmaceuticals Ltd
NSE: JBCHEPHARM BSE: 506943
₹1991.20
(-0.34%)
Sun, 26 Apr 2026, 04:59 pm
Market Cap320.69B
PE Ratio41.96
Dividend0.99
Health Technology
Pharmaceuticals: Major
24.5KJ B Chemicals & Pharmaceuticals Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are well covered by earnings (6.7x coverage).
- Dividends after 3 years are expected to be well covered by earnings (5.8x coverage).
- J. B. Chemicals & Pharmaceuticals's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- J. B. Chemicals & Pharmaceuticals's dividend is below the markets top 25% of dividend payers in India (3.08%).
future
- J. B. Chemicals & Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 7.2%.
- J. B. Chemicals & Pharmaceuticals's earnings are expected to exceed the low risk growth rate next year.
- Performance (ROE) is expected to be above the current IN Pharmaceuticals industry average.
- An improvement in J. B. Chemicals & Pharmaceuticals's performance (ROE) is expected over the next 3 years.
- J. B. Chemicals & Pharmaceuticals's revenue growth is expected to exceed the India market average.
- Cash flow for J. B. Chemicals & Pharmaceuticals is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals's earnings are expected to grow by 12.8% yearly, however this is not considered high growth (20% yearly).
- J. B. Chemicals & Pharmaceuticals's earnings growth is positive but not above the India market average.
- J. B. Chemicals & Pharmaceuticals's net income is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
- J. B. Chemicals & Pharmaceuticals's revenue is expected to increase but not above the 50% threshold in 2 years time.
- J. B. Chemicals & Pharmaceuticals's revenue is expected to grow by 12.1% yearly, however this is not considered high growth (20% yearly).
health
- J. B. Chemicals & Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- J. B. Chemicals & Pharmaceuticals is profitable, therefore cash runway is not a concern.
- J. B. Chemicals & Pharmaceuticals is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (583.5%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 25.9x debt.
- J. B. Chemicals & Pharmaceuticals's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (11.8% vs 3% today).
- J. B. Chemicals & Pharmaceuticals earns more interest than it pays, coverage of interest payments is not a concern.
- J. B. Chemicals & Pharmaceuticals's level of debt (3%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the J. B. Chemicals & Pharmaceuticals board of directors is about average.
- Jyotindra's compensation has been consistent with company performance over the past year, both up more than 20%.
- Jyotindra's remuneration is higher than average for companies of similar size in India.
misc
- J. B. Chemicals & Pharmaceuticals has significant price volatility in the past 3 months.
past
- J. B. Chemicals & Pharmaceuticals's 1-year earnings growth exceeds its 5-year average (49.3% vs 14.3%)
- J. B. Chemicals & Pharmaceuticals's year on year earnings growth rate has been positive over the past 5 years.
- J. B. Chemicals & Pharmaceuticals used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- J. B. Chemicals & Pharmaceuticals has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- J. B. Chemicals & Pharmaceuticals's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (49.3% vs 22.7%).
- J. B. Chemicals & Pharmaceuticals has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- JBCHEPHARM outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- JBCHEPHARM outperformed the Market in India which returned -14.5% over the past year.
- NSEI:JBCHEPHARM is up 13.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- NSEI:JBCHEPHARM is up 13.3% outperforming the market in India which returned 8% over the past month.
- J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- J. B. Chemicals & Pharmaceuticals's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- J. B. Chemicals & Pharmaceuticals is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- J. B. Chemicals & Pharmaceuticals is poor value based on expected growth next year.
- J. B. Chemicals & Pharmaceuticals is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- J. B. Chemicals & Pharmaceuticals is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800